Empagliflozin also has the benefits of reducing this obese patient's weight, BP, and HbA1c without the risks of hypoglycemia (this is a pro compared to secretagogues, TZDs, and insulin which tend to increase weight) but he should be counseled about the signs of ketoacidosis
To view or add a comment, sign in 8,202 followers Explore related topics Trends in Glp-1 Treatment Options Impact of Glp-1 Medications on Health How Glp-1 Drugs Impact Economic Trends Advancements in Diabetes and Obesity Treatments Innovations in Diabetes Care and Insulin Management Trends in Weight Loss Drug Accessibility Tirzepatide impact on drug pricing Latest Strategies for Diabetes Management Medication Safety Practices Latest Developments in Type 1 Diabetes Research
Major online marketplaces and wellness retailers have increased monitoring of supplement labeling and promotional terminology associated with GLP-1 support claims
Balancing GLP-1 risks and benefits: physician perspectives Muscle loss is among several concerns that physicians have around GLP-1s
Sclerostin regulation, microarchitecture, and advanced glycation end-products in the bone of elderly women with type 2 diabetes